busulfan has been researched along with Adenocarcinoma in 18 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both busulfan treatment doses caused earlier occurrence of persistent estrus, with dose-dependence as compared to controls." | 5.33 | Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. ( Maekawa, A; Shirota, M; Taya, K; Watanabe, G; Yoshida, M, 2005) |
| "From 1977 until 1980, 179 patients with newly diagnosed FIGO stages IIB, III or IV ovarian adenocarcinoma were randomized in a two-armed clinical trial: dihydroxybusulfan (B) 600 mg/m2 p." | 5.05 | A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. ( Aabo, K; Dombernowsky, P; Hald, I; Hansen, HH; Hørbov, S; Lundvall, F; Nielsen, NC; Sørensen, BL; Sørensen, HM, 1985) |
| "In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma." | 3.72 | The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. ( Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004) |
| "Both busulfan treatment doses caused earlier occurrence of persistent estrus, with dose-dependence as compared to controls." | 1.33 | Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats. ( Maekawa, A; Shirota, M; Taya, K; Watanabe, G; Yoshida, M, 2005) |
| "We report three patients with relapsed ovarian cancer who developed femoral head necrosis requiring endoprosthetic hip surgery 16-35 months after high-dose chemotherapy (HDC) with treosulfan (47 and 56 g/m(2) body-surface area (BSA)) given as 3-25 h infusions and followed by autologous peripheral blood stem cell (PBSC) transplantation." | 1.32 | Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation. ( Bojko, P; Dirsch, O; Hilger, RA; Ruehm, SG; Scheulen, ME; Seeber, S, 2003) |
| " To our knowledge, this is one of the few cases of ROC in which partial remissions using conventionally dosed chemotherapy were achieved repeatedly despite a unfavorable relapse-free interval after high-dose chemotherapy for primary disease." | 1.31 | Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. ( Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (55.56) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bojko, P | 1 |
| Hilger, RA | 1 |
| Ruehm, SG | 1 |
| Dirsch, O | 1 |
| Seeber, S | 1 |
| Scheulen, ME | 1 |
| CLIFFORD, P | 1 |
| BHARDWAJ, BV | 1 |
| WHITTAKER, LR | 1 |
| Knight, LA | 1 |
| Di Nicolantonio, F | 1 |
| Whitehouse, P | 1 |
| Mercer, S | 1 |
| Sharma, S | 1 |
| Glaysher, S | 1 |
| Johnson, P | 1 |
| Cree, IA | 1 |
| Yoshida, M | 1 |
| Watanabe, G | 1 |
| Shirota, M | 1 |
| Maekawa, A | 1 |
| Taya, K | 1 |
| Aksoy, M | 1 |
| Erdem, S | 1 |
| Bakioğlu, I | 1 |
| Dincol, G | 1 |
| Double, JA | 1 |
| Bibby, MC | 1 |
| Khalil, A | 1 |
| Ciobanu, N | 1 |
| Sparano, JA | 1 |
| Gucalp, R | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Klumpp, TR | 1 |
| Mangan, KF | 1 |
| Glenn, LD | 1 |
| Macdonald, JS | 1 |
| Petty, R | 1 |
| Evans, A | 1 |
| Duncan, I | 1 |
| Kurbacher, C | 1 |
| Cree, I | 1 |
| Breidenbach, M | 1 |
| Rein, DT | 1 |
| Mallmann, P | 1 |
| Kurbacher, CM | 1 |
| Storb, R | 1 |
| Weiden, PL | 1 |
| Graham, TC | 1 |
| Thomas, ED | 1 |
| Fennelly, J | 1 |
| Behr, J | 1 |
| Thyselius, D | 1 |
| Jäger, W | 1 |
| Paterok, EM | 1 |
| Papineschi, F | 1 |
| Bonini, R | 1 |
| Pistolisi, D | 1 |
| Spremolla, G | 1 |
| Aabo, K | 1 |
| Hald, I | 1 |
| Hørbov, S | 1 |
| Dombernowsky, P | 1 |
| Hansen, HH | 1 |
| Sørensen, HM | 1 |
| Lundvall, F | 1 |
| Nielsen, NC | 1 |
| Sørensen, BL | 1 |
| Visfeldt, J | 1 |
| Lundwall, F | 1 |
| Firusian, N | 1 |
| Reis, HE | 1 |
| Gallmeier, W | 1 |
| Schmidt, CG | 1 |
| Struck, RF | 1 |
2 reviews available for busulfan and Adenocarcinoma
| Article | Year |
|---|---|
Studies of marrow transplantation in dogs.
Topics: Adenocarcinoma; Anal Gland Neoplasms; Animals; Blood Transfusion; Bone Marrow Cells; Bone Marrow Tra | 1976 |
[Primary metastasizing fallopian tube carcinoma. Case report and overview of current therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Busulfan; Cisplat | 1990 |
3 trials available for busulfan and Adenocarcinoma
| Article | Year |
|---|---|
Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Trans | 1995 |
Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; | 1993 |
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria | 1985 |
13 other studies available for busulfan and Adenocarcinoma
| Article | Year |
|---|---|
Femoral head necrosis in three patients with relapsed ovarian cancer receiving high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Alkylating; Busulfan; Combined Modality Therapy; Femal | 2003 |
INTENSIVE NITROGEN MUSTARD THERAPY WITH ABDOMINAL AORTIC OCCLUSION IN NASOPHARYNGEAL CARCINOMA.
Topics: Adenocarcinoma; Antineoplastic Agents; Aorta; Aorta, Abdominal; Busulfan; Carcinoma; Carcinoma, Squa | 1965 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 2004 |
Reduction of primordial follicles caused by maternal treatment with busulfan promotes endometrial adenocarcinoma development in donryu rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Atrophy; Busulfan; Endometrial Neoplasms | 2005 |
Endometrial cancer due to busulfan therapy. Report of two cases.
Topics: Adenocarcinoma; Busulfan; Carcinoma; Female; Humans; Leukemia, Myeloid; Middle Aged; Uterine Neoplas | 1984 |
Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Busulfan; Colonic Neoplasms; Cyclophosphamide; Dose- | 1983 |
Drug resistance in ovarian cancer - the role of p53.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Co | 1998 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycyt | 2002 |
Treosulfan (dihydroxybusulphan) in the management of ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Busulfan; Cystadenocarcinoma; Female; Humans; Middle Aged; Ovarian Neop | 1977 |
[Chronic myeloid leukemia and carcinoma of the prostate].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Busulfan; Cyproterone; Cyproterone Acetate; Humans; Leuk | 1989 |
Alteration of karyotypic profiles in human cancerous effusion following treatment with antineoplastic drug.
Topics: Adenocarcinoma; Ascitic Fluid; Busulfan; Chromosomes; Female; Humans; Karyotyping; Lymphatic Metasta | 1970 |
[Syntropy of malignant diseases with hemoblastosis].
Topics: Adenocarcinoma; Aged; Busulfan; Estradiol; Female; Humans; Immunosuppressive Agents; Kidney Neoplasm | 1970 |
Synthesis of potential antineoplastic agents. 35. Phosphorus-containing structural analogs of myleran.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Busulfan; Carcinoma 256, Walker; Chemistry, Organic; | 1966 |